ABVX

Abivax ADR

90.23

Oct 22 • 3:59 PM ET -3.26 (-3.49%)

91.26

Aftermarket • 7:54 PM ET +1.03 (1.14%)

Healthcare Biotechnology France Mid NASD

Peers: SYRE ROIV ABBV BMY PFE JNJ LLY IMVT TEVA MRK

| Held by: IBB GVIP ORR MSSM ONEQ FRTY AADR MEDI GURU VGK

Scroll to Statements

Index	-
Market Cap	7.90B
Enterprise Value	7.44B
Income	-467.86M
Sales	0.00M
Book/sh	5.25
Cash/sh	5.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	69
IPO	Oct 20, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	17.20
P/C	17.17
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.97
Current Ratio	5.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-6.10
EPS next Y	-3.94
EPS next Q	-0.92
EPS this Y	24.76%
EPS next Y	5.33%
EPS next 5Y	34.25%
EPS past 3/5Y	-17.73% -12.77%
Sales past 3/5Y	- -
EPS Y/Y TTM	-101.86%
Sales Y/Y TTM	-
EPS Q/Q	-98.18%
Sales Q/Q	-
Earnings	Sep 21 AMC
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	9.41%
Insider Trans	0.00%
Inst Own	55.94%
Inst Trans	10.89%
ROA	-139.89%
ROE	-258.43%
ROIC	-111.69%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.01%
SMA50	-13.22%
SMA200	-21.58%
Trades

Shs Outstand	79.82M
Shs Float	79.31M
Short Float	9.81%
Short Ratio	6.87
Short Interest	7.78M
52W High	148.83 -39.37%
52W Low	69.81 29.25%
Volatility	5.43% 4.41%
ATR (14)	4.47
RSI (14)	42.79
Beta	1.24
Rel Volume	0.79
Avg Volume	1.13M
Volume	896,149

Perf Week	-2.33%
Perf Month	-4.14%
Perf Quarter	-28.22%
Perf Half Y	-20.15%
Perf YTD	-33.09%
Perf Year	-0.53%
Perf 3Y	987.11%
Perf 5Y	-
Perf 10Y	-
Recom	1.28
Target Price	157.26
Prev Close	93.49
Price	90.23
Change %	-3.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-26	Upgrade	Jefferies	Hold → Buy	$158
Jun-02-26	Upgrade	Wedbush	Underperform → Neutral	$90
Jun-02-26	Downgrade	Jefferies	Buy → Hold	$90
Mar-16-26	Initiated	Jefferies	Buy	$160
Feb-24-26	Initiated	Wedbush	Outperform	$110
Nov-24-25	Initiated	Truist	Buy
Nov-06-25	Initiated	Wolfe Research	Outperform	$176
Oct-13-25	Initiated	Barclays	Overweight	$142
Jul-23-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Mar-20-25	Initiated	Morgan Stanley	Equal-Weight	$12
Dec-04-24	Initiated	JMP Securities	Mkt Outperform	$33
Jul-29-24	Initiated	Laidlaw	Buy	$48
May-20-24	Initiated	BTIG Research	Buy	$43
Apr-29-24	Initiated	Piper Sandler	Overweight	$42
Apr-29-24	Initiated	Guggenheim	Buy	$50
Nov-14-23	Initiated	Morgan Stanley	Equal-Weight	$15
Nov-14-23	Initiated	Leerink Partners	Outperform	$20

Show Previous Ratings

Sep-30-26 04:05PM	Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 (GlobeNewswire)
Sep-21-26 04:05PM	Abivax Presents Business Updates and First Half 2026 Financial Results (GlobeNewswire)
Sep-11-26 09:15AM	Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q2 2026 Result (GuruFocus.com)
Jul-30-26 04:05PM	Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod (GlobeNewswire)
Jul-23-26 04:05PM	Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments (GlobeNewswire)
09:35AM	Loading…
Jul-10-26 09:35AM	Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma (Quartz)
Jul-06-26 04:05PM	Abivax Announces Closing of $920 Million Public Offering (GlobeNewswire)
Jul-02-26 06:30AM	ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet Buyout Chatter Builds (Stocktwits) +9.12%
04:20AM	Abivax jumps as fully exercised option lifts share-sale haul to $920 million (Investing.com)
02:00AM	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (807M) (GlobeNewswire)
Jul-01-26 12:00PM	Jefferies upgrades Abivax to Buy, lifts PT as safety concerns over obefazimod ease (Investing.com)
10:23AM	Abivax Prices $800M Offering Of ADS Heres A Look At Some Key Figures (Stocktwits)
09:06AM	Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares (GlobeNewswire)
08:56AM	Abivax announces trading resumption of its ordinary shares on Euronext Paris (GlobeNewswire)
08:37AM	Abivax Announces Pricing of Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares (GlobeNewswire)
05:18AM	Loading…
05:18AM	Abivax shares surge as worries subside over immune drugs cancer risk (BioPharma Dive)
01:30AM	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris (GlobeNewswire)
12:56AM	From Cancer Scare to Comeback, Abivax Shares Erase a Month of Losses in a Day (BeInCrypto)
Jun-30-26 08:13PM	ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns (Stocktwits) +38.60%
04:45PM	Abivax Announces Launch of Public Offering of American Depositary Shares (GlobeNewswire)
04:26PM	Abivax Stock Soars 36% After Trial Update Eases Cancer Concerns (GuruFocus.com)
01:15PM	Abivax shares jump as updated trial data eases safety concerns (Proactive)
09:25AM	Abivax stock surges on obefazimod safety data, cancer concerns (Quartz)
08:59AM	Abivax shares jump 36% as new trial data support ulcerative colitis drug obefazimod (Euronews)
08:11AM	Nasdaq leads Wall Street higher as second quarter ends (Proactive)
Jun-29-26 07:55PM	ABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Data (Stocktwits)
06:27PM	?? Under the Radar: Abivax Shares Rise on Expanded Safety Data for Ulcerative Colitis Drug (The Wall Street Journal)
04:05PM	Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database (GlobeNewswire)
Jun-18-26 07:45AM	cAMPfield lands $180M to build gut disease drug (BioPharma Dive)
Jun-04-26 12:36PM	European shares rise as oil slips, investors watch Middle East (Reuters) +16.39%
08:01PM	Loading…
Jun-02-26 08:01PM	ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: Pharma Bro Says GLPs Are Doing Fine After Similar Fears (Stocktwits) -44.10% +24.34%
03:26PM	Abivax Drops 32% As Cancer Cases Cloud Key Drug Trial (GuruFocus.com)
11:14AM	Abivax Grounded as Cancer Cases Cast a Shadow Over Best-in-Class Trial Data (Moby)
10:12AM	Abivax stock plunges on cancer signal in ulcerative colitis trial (Quartz)
10:12AM	Abivax stock plunges after cancer cases cloud bowel disease drug trial (Quartz)
09:43AM	Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls (The Fly)
07:50AM	Abivax Drops 32% On Cancer Signal: Jefferies Warns Of Real Overhang But Retail Calls Selloff An Overreaction (Stocktwits)
06:23AM	Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX) (InvestorsHub)
03:58AM	Abivax stock plunges 32% as rare malignancy events cloud solid colitis trial data (Investing.com)
Jun-01-26 06:56PM	ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial Rare Cancer Concerns Hit Sentiment (Stocktwits)
04:05PM	Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis (GlobeNewswire)
May-22-26 04:05PM	Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis (GlobeNewswire)
May-11-26 04:05PM	Abivax Announces Results of its May 11, 2026 Annual General Meeting (GlobeNewswire)
May-05-26 02:00AM	Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (38.5M) Offering of American Depositary Shares (GlobeNewswire) +5.68%
Apr-22-26 04:05PM	Abivax to Present Data on Obefazimod at Digestive Disease Week (GlobeNewswire)
Apr-20-26 04:05PM	Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents (GlobeNewswire)
Apr-01-26 04:05PM	Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies (GlobeNewswire)
Mar-23-26 04:05PM	Abivax Announces Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-12-26 02:55PM	Abivax Pushes Back On Takeover Rumors (Moby)
Mar-03-26 08:07AM	Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-24-26 09:39AM	Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls (The Fly)
Feb-21-26 06:00AM	Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 (GlobeNewswire)
Feb-02-26 09:51PM	ABIVAX Societe Anonyme (ABVX): A Bull Case Theory (Insider Monkey)
04:16AM	ABIVAX Societe Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs (Insider Monkey)
Jan-30-26 03:50PM	Better Long-Term Buy: This Emerging Player or the Industry Leader? (Motley Fool)
Jan-19-26 04:05PM	Prediction: This Healthcare Stock Could Soar by 72% in 2026 (Motley Fool)
Jan-13-26 10:37AM	Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds (Benzinga)
05:59AM	JPM26: Day 1 drug prices and policy changes drive the agenda (Pharmaceutical Technology)
Jan-12-26 02:32PM	Stocks to Watch Monday: Capital One, UnitedHealth, Walmart, Exxon (The Wall Street Journal)
02:32PM	Stocks to Watch Monday Recap: Capital One, UnitedHealth, Walmart, Exxon (The Wall Street Journal)
01:20PM	This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. (Barrons.com)
11:17AM	JPM26: Eli Lilly reportedly eyes 15bn takeover of Abivax (Pharmaceutical Technology)
06:14AM	Abivax shares surge after report flags continued Eli Lilly takeover interest (Investing.com)
05:03AM	Abivax Surges on Report Ely Lilly is Preparing $17.5 Billion Bid (The Wall Street Journal)
05:03AM	Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid (The Wall Street Journal)
Jan-11-26 01:00AM	ABIVAX Societe Anonyme (ABVX) Rumored To Attract Interest From Eli Lilly (Insider Monkey)
Jan-07-26 04:05PM	Abivax Provides 2026 Corporate Outlook (GlobeNewswire) +6.20% -8.69%
Dec-31-25 11:25AM	Is ABIVAX Societe Anonyme (ABVX) One of the Hottest Large-Cap Stocks of 2025? (Insider Monkey)
11:20AM	Could This Potential Move Boost Eli Lilly's Prospects? (Motley Fool)
Dec-28-25 10:05AM	Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout (Insider Monkey)
Dec-22-25 07:29PM	Why Abivax Stock Was on Fire Today (Motley Fool) +20.69%
04:59AM	Abivax soars on report of Eli Lilly meeting French officials over possible deal (Investing.com)
Dec-18-25 04:05PM	Abivax to be Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-25 04:05PM	Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings (GlobeNewswire)
Dec-15-25 04:08PM	Abivax Presents Third Quarter 2025 Financial Results (GlobeNewswire) -6.08% -5.88%
Dec-12-25 07:15AM	Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q3 2025 Result (GuruFocus.com) -5.67%
Dec-09-25 05:05PM	2 Under-the-Radar Stocks That Have Soared This Year (Motley Fool) +6.94%
Dec-04-25 12:54PM	The 1,300% Biotech Shockwave That Turned $500 Million Into $8 Billion (GuruFocus.com)
12:00AM	Europes Biotech Standout Faces Crucial Year After 1,300% Rally (Bloomberg)
Nov-13-25 12:00PM	Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? (Zacks)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:05PM	Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis (GlobeNewswire)
Oct-19-25 03:09AM	Barclays Initiates ABIVAX Societe (ABVX) With Overweight Rating (Insider Monkey)
Oct-06-25 05:17PM	Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease (Investor's Business Daily)
04:00AM	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies (GlobeNewswire)
Oct-05-25 11:00AM	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data (GlobeNewswire)
Oct-01-25 02:27AM	Citizens JMP Raises PT on ABIVAX Societe Anonyme (ABVX) Stock (Insider Monkey)
Sep-30-25 12:47PM	ABIVAX Societe Anonyme (ABVX) to Present Phase 3 UC Data at UEG Congress, Investor Call Scheduled (Insider Monkey)
Sep-29-25 04:05PM	Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting (GlobeNewswire)
Sep-23-25 04:05PM	Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting (GlobeNewswire)
Sep-12-25 11:45AM	Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review (GlobeNewswire)
Sep-08-25 04:00PM	Abivax Presents First Half 2025 Financial Results (GlobeNewswire)
Aug-30-25 05:30AM	How Hedge Funds Won Big on an Obscure Drugmaker (The Wall Street Journal)
Aug-01-25 06:46AM	Piper Sandler Raised the Firm's PT on ABIVAX Societe (ABVX), Kept an Overweight Rating (Insider Monkey)
Jul-31-25 11:31PM	Piper Sandler Raises Price Target for Abivax (ABVX) (Insider Monkey)
10:00AM	This Stock Is Up by 800% This Year -- but Is It a Buy? (Motley Fool)
Jul-28-25 04:15PM	Abivax Announces Closing of $747.5 Million Public Offering (GlobeNewswire)
Jul-25-25 02:00AM	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M) (GlobeNewswire)
Jul-24-25 04:02PM	Abivax (ABVX) Skyrockets 586% to New High on Promising Drug Trial, Bullish Analyst Outlooks (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sofinnova Crossover I SLP	Affiliate	Jan 08 '26	Proposed Sale	133.70	1,000,000	133,700,000		Jan 08 09:21 AM
Sofinnova Crossover I SLP	Affiliate	Oct 28 '25	Proposed Sale	92.75	1,200,000	111,300,000		Oct 28 11:11 AM

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

CEO & DirectorMr. Marc M. P. de Garidel M.B.A.

EVPMr. Didier Blondel

Chief Technical OfficerMr. Timothy P. Kelly M.B.A.

Senior VP & Head of Investor RelationsMr. Patrick Malloy

Chief People & Compliance OfficerMs. Ida Hatoum

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVX

Abivax ADR

Upgrade your Finviz experience